A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

NCT02289703 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC

Collaborators